Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma

J Nucl Med. 1995 May;36(5):807-10.

Abstract

After intravenous administration of a radiolabeled somatostatin analog (octreotide), an image of the thyroid gland is frequently observed; few data are available, however, on somatostatin receptors in epithelial thyroid cells assessed in vitro and on images of differentiated thyroid carcinoma (DTC) with pentetreotide scintigraphy.

Methods: In four patients with metastatic thyroid carcinoma, whole-body scintigraphy was performed 4 to 48 hr after injection of 110 MBq of 111In-pentetreotide. The results were compared to data obtained with other imaging modalities, including scintigraphy performed after administration of a therapeutic dose of 131I.

Results: There were positive foci in distant metastases on 111In-pentetreotide scintigraphy. Pentetreotide scintigraphy was positive in two patients with an "insular" form of DTC, one of whom had a positive (faintly) 131I scan. Of the other two patients with papillary DTC without radioiodine uptake, only one exhibited a certain degree of pentetreotide scintigraphy positivity in distant metastases.

Conclusion: These results show promise for exploration of insular thyroid carcinoma and suggest that these carcinomas may possess functional differentiation features, including somatostatin receptors.

Publication types

  • Case Reports

MeSH terms

  • Bone Neoplasms / metabolism
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary
  • Humans
  • Indium Radioisotopes*
  • Iodine Radioisotopes / therapeutic use
  • Male
  • Middle Aged
  • Radionuclide Imaging
  • Receptors, Somatostatin / analysis
  • Somatostatin / analogs & derivatives*
  • Thyroid Neoplasms / diagnostic imaging*
  • Thyroid Neoplasms / metabolism
  • Thyroid Neoplasms / pathology
  • Whole-Body Counting

Substances

  • Indium Radioisotopes
  • Iodine Radioisotopes
  • Receptors, Somatostatin
  • Somatostatin
  • pentetreotide